ARTHAM THERAPEUTICS
ARTham Therapeutics creates value by developing medicines that are disease-modifying and improve patient health. They operate a virtual research and development model that seeks innovation through academic and business partners.
ARTHAM THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2018-07-01
Address:
Yokohama, Kanagawa, Japan
Country:
Japan
Website Url:
http://www.arthamther.com
Total Employee:
11+
Status:
Active
Contact:
81-45-225-8858
Technology used in webpage:
Euro Pound Sterling Japanese Yen Japanese Server Location
Similar Organizations
Clexio Biosciences
Clexio Biosciences is a clinical-stage pharmaceutical company that integrates drugs and new technologies to deliver clinical benefits.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Investors List
Oita Venture Capital
Oita Venture Capital investment in Series A - ARTham Therapeutics
Takeda Ventures
Takeda Ventures investment in Series A - ARTham Therapeutics
Miyako Capital
Miyako Capital investment in Series A - ARTham Therapeutics
Mizuho Capital
Mizuho Capital investment in Series A - ARTham Therapeutics
SMBC Venture Capital
SMBC Venture Capital investment in Series A - ARTham Therapeutics
Official Site Inspections
http://www.arthamther.com
- Host name: www3976.sakura.ne.jp
- IP address: 163.43.87.216
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062

More informations about "ARTham Therapeutics"
ARTham Therapeutics - Crunchbase Company Profile
ARTham Therapeutics creates value by developing medicines that are disease-modifying and improve patient health. They operate a virtual research and …See details»
ARTham Therapeutics - Overview, News & Similar companies
Who is ARTham Therapeutics. ARTham Therapeutics is a clinical stage biopharmaceutical company that will deliver "medicines that matter" for patients, with a compelling portfol io …See details»
ARTham Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Explore ARTham Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, and 8 literature, Technology Platform:Small ...See details»
ARTham Therapeutics, Inc Overview | SignalHire Company Profile
ARTham Therapeutics, Inc headquarters is in Yokohama, Kanagawa. ARTham Therapeutics, Inc is in the sectors of: Biotech. To connect with ARTham Therapeutics, Inc's employee register …See details»
ARTham Therapeutics - PitchBook
ARTham Therapeutics General Information Description. Developer of novel drugs and medicines intended to combat debilitating diseases. The company's drugs are used to treat inflammatory …See details»
ARTham Therapeutics - Products, Competitors, Financials, …
ARTham Therapeutics engages in the discovery and development of disease-modifying drugs through a virtual research and development model, targeting unmet medical needs with a …See details»
ARTham Therapeutics - VentureRadar
Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and MGI Pharma, a biopharmaceutical company focused on …See details»
ARTham Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials ...
Explore ARTham Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials.See details»
ARTham Therapeutics Inc Asset Profile | Preqin
Founded in 2018 and based in Kanagawa, Japan, ARTham Therapeutics Inc develops pharmaceuticals address to diseases like Non-alcoholic Steatohepatitis, and va...See details»
ARTham Therapeutics - Craft
ARTham Therapeutics has 5 employees at their 1 location. See insights on ARTham Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
UMIN Clinical Trials Registry
Apr 1, 2022 Key exclusion criteria; 1)Patients for whom MRI scan is difficult or impossible to perform and whose lesions are difficult to be evaluated by MRI due to artifacts (e.g., patients …See details»
ARTham Therapeutics株式会社 貸借対照表 Balance Sheet
As of March 31, 2019 ; 単位:円/Yen) 資産の部. ASSETS . 流動資産. Current Assets : 現金及び預金. Cash and deposits : 486,090,990 Prepaid expenses ...See details»
ARTham Therapeutics, Inc. (ARTham Therapeutics, Inc.) - 药物管 …
了解ARTham Therapeutics, Inc. (ARTham Therapeutics, Inc.)公司的药物管线,治疗领域,技术平台,以及它的4项临床试验, 1篇新闻和6篇文献,技术平台:小分子化药,药物:ART-001,TAK …See details»
第5期 決算公告 - ARTham Ther
第5期 決算公告 - ARTham TherSee details»
Springboard Program in Yokohama 2019 Demo Day
Sep 18, 2019 CONNECT with San Diego Venture Group . CONNECT and San Diego Venture Group, two major supporting institutions in San Diego, merged in April 2019. CONNECT is an …See details»
医学研究に関する情報公開 - ARTham Ther
医学研究に関する情報公開 アーサムセラピューティクスでは、患者さんなどからご提供いただいた組織、細胞あるSee details»
ARTham Therapeutics Inc. - Google Search
Www.arthamther.com › en_news. ... ARTham Therapeutics - Crunchbase Company Profile & Funding. www.crunchbase.com › organization › artham-therapeutics. ARTham Therapeutics …See details»
ARTham Therapeutics株式会社の情報 | 官報決算データベース
純利益: 2,689万7,000円 ( 24.61%) 利益剰余金: 13億1,629万8,000円 (+2.09%) 総資産: 16億7,164万5,000円 (+3.34%)See details»
A0 R2 Financial statement 税金確定前 - ARTham Ther
個別注記表 Notes To The Financial Statements 自 2021年 4月 1日 From: April 1, 2021 至 2022年 3月31日 To: March 31, 2022 1. Notes on the matters concerning significant accounting policiesSee details»
A0 R2 Financial statement 税金確定前 - ARTham Ther
個別注記表 Notes To The Financial Statements 自. 令和2年4月1日 From: April 1, 2020 至. 令和. 3年3月31日 To: March 31, 2021 . 1. Notes on the matters concerning significant accounting …See details»